Premium
Leigh syndrome: Clinical features and biochemical and DNA abnormalities
Author(s) -
Rahman S.,
Blok R. B.,
Dahl H.H. M.,
Danks D. M.,
Kirby D. M.,
Chow C. W.,
Christodoulou J.,
Thorburn D. R.
Publication year - 1996
Publication title -
annals of neurology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.764
H-Index - 296
eISSN - 1531-8249
pISSN - 0364-5134
DOI - 10.1002/ana.410390311
Subject(s) - leigh disease , heteroplasmy , mitochondrial dna , genetics , consanguinity , biology , pedigree chart , point mutation , mutation , gene
We investigated the etiology of Leigh syndrome in 67 Australian cases from 56 pedigrees, 35 with a firm diagnosis and 32 with some atypical features. Biochemical or DNA defects were determined in both groups, ie, 80% in the tightly defined group and 41% in the “Leigh‐like” group. Eleven patients had mitochondrial DNA point mutations (nucleotide [nt] 8993 T to G, nt 8993 T to C, or nt 8344 A to G) and 1 Leigh‐like patient had a heteroplasmic deletion. Twenty‐nine patients had enzyme defects, ie, 13 respiratory chain complex I, 9 complex IV, and 7 pyruvate dehydrogenase complex (PDHC). Complex I deficiency is more common than recognized previously. Six PDHC‐deficient patients had mutations in the X‐chromosomal gene encoding the Elα subunit of PDHC. Parental consanguinity suggested autosomal recessive inheritance in two complex IV‐deficient sibships. We found no strong correlation between the clinical features and basic defects. An assumption of autosomal recessive inheritance (frequently made in the past) would have been wrong in nearly one‐half (1 1 of 28 tightly defined and 18 of 41 total patients) of those in whom a cause was found. A specific defect must be identified if reliable genetic counseling is to be provided.